Thomas Lander

Lipid Therapeutics GmbH develops therapies for inflammatory diseases of the digestive system. Its product is LT-02, a delayed release of Phosphatidylcholine, for the treatment of Ulcerative colitis based on the preclinical and clinical work conducted by Prof. Stremmel from the University Hospital Heidelberg. The company was founded in 2008 and is headquartered in Heidelberg, Germany.

Boehringer Ingelheim AB develops, produces, markets and sells pharmaceutical products. The firm also provides research, development, manufacturing and marketing services in the therapeutic field of human and veterinary medicine. The company was founded in 1967 is headquartered in Stockholm, Germany.

CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany.

Tuebingen Scientific Medical GmbH develops, produces and markets instruments and accessories for minimally invasive surgery. The company was founded by Marc O. Schurris in 2001 and is headquartered in Tübingen, Germany.

vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany.